1,3,4, Oxadiazole Compound A3 Provides Robust Protection Against PTZ-Induced Neuroinflammation and Oxidative Stress by Regulating -Pathway
Overview
Affiliations
Background: Epilepsy is a common neurological disorder that is characterized by recurrent episodes of seizures. Various studies have demonstrated a direct association between oxidative stress and inflammation in several neurological disorders including epilepsy. This study aimed to investigate the neuroprotective effects of a synthetic 1,3,4, oxadiazole compound A3 against pentylenetetrazole (PTZ)-induced kindling and seizure model.
Methodology: PTZ was administered in a sub-convulsive dose of 40 mg/kg for 15 days, at 48-hour intervals to male Swiss-Albino mice until animals were fully kindled. Two different doses of A3 (10 mg/kg and 30 mg/kg) were administered to find out the effective dose of A3 and to further demonstrate the relative role of nuclear factor E2-related factor () in the PTZ-induced kindled model.
Results: Our results demonstrated a compromised antioxidant capacity associated with a low level of catalase (CAT), superoxide dismutase (SOD), glutathione (GST), and glutathione S-transferase (GSH) in the kindled group. However, the PTZ-induced group demonstrated an elevated level of lipid peroxidation (LPO) level parallel to pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), mediators as cyclooxygenase (COX-2), and nuclear factor kappa B (NFκB). Furthermore, the A3 treatment reversed these changes and overexpressed the antioxidant gene and its downstream . To further investigate the involvement of , we employed an -inhibitor, ie, all-trans retinoic acid (ATRA), that further aggravated the PTZ toxicity. Moreover, vascular endothelial growth factor (VEGF) expression was evaluated to assess the extent of BBB disruption.
Conclusion: The findings of this study suggest that A3 could mediate neuroprotection possibly by activating dependent downregulation of inflammatory cascades.
Sheng M, Chen X, Yu Y, Wu Q, Kou J, Chen G Front Pharmacol. 2023; 14:1102567.
PMID: 37063298 PMC: 10102520. DOI: 10.3389/fphar.2023.1102567.
Alyami N, Abdi S, Alyami H, Almeer R Neurochem Res. 2022; 47(10):3012-3023.
PMID: 35838827 DOI: 10.1007/s11064-022-03647-4.
Carveol Promotes Nrf2 Contribution in Depressive Disorders through an Anti-inflammatory Mechanism.
Muhammad A, Hao L, Al Kury L, Ur Rehman N, Alvi A, Badshah H Oxid Med Cell Longev. 2022; 2022:4509204.
PMID: 35295720 PMC: 8920705. DOI: 10.1155/2022/4509204.